Turofexorate Isopropyl 2 mg | Purity Not Available
TargetMol
Turofexorate Isopropyl (XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM
More Information Supplier PageTurofexorate Isopropyl
Search Results
Turofexorate Isopropyl 25 mg | Purity Not Available
TargetMol
Turofexorate Isopropyl (XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM
More Information Supplier PageTurofexorate Isopropyl
Turofexorate Isopropyl 10 mg | Purity Not Available
TargetMol
Turofexorate Isopropyl (XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM
More Information Supplier PageTurofexorate Isopropyl
GW 441756 5 mg | Purity Not Available
TargetMol
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
More Information Supplier PageGW 441756
GW 441756 50 mg | Purity Not Available
TargetMol
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
More Information Supplier PageGW 441756
Turofexorate Isopropyl 5 mg | Purity Not Available
TargetMol
Turofexorate Isopropyl (XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM
More Information Supplier PageTurofexorate Isopropyl
Neflamapimod 10 mg | 99.02%
TargetMol
VX-745, a specific and effective inhibitor of p38α(IC50=10 nM), is 22-fold greater specificity against p38β and no inhibition activity to p38γ.
More Information Supplier PageNeflamapimod
Neflamapimod 25 mg | 99.02%
TargetMol
VX-745, a specific and effective inhibitor of p38α(IC50=10 nM), is 22-fold greater specificity against p38β and no inhibition activity to p38γ.
More Information Supplier PageNeflamapimod
Telatinib 10 mg | 98.95%
TargetMol
Telatinib is an effective inhibitor of VEGFR2/3, c-Kit, and PDGFRα. The IC50s of Telatinib forVEGFR2/3, c-Kit and PDGFRα are 6 nM/4 nM, 1 nM, and 15 nM, respectively.
More Information Supplier PageTelatinib
Ruxolitinib (S enantiomer) 5 mg | 99.50%
TargetMol
Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.
More Information Supplier PageRuxolitinib (S enantiomer)
